ResearcherFox Chase Cancer CenterActive in the last 2 years
Fa-Chyi Lee
Matched on ORCID iD 0000-0003-1912-3441; OpenAlex author ID A5005238877. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 6
- Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.jvir.2026.108954↗
- Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7333↗
- Case Report: A complete pathologic response in pancreatic cancer with squamous cell differentiation. Last author DOI 10.3389/fonc.2023.1240405↗
- BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Co-author DOI 10.3390/cancers14102453↗
- A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve… Co-author DOI 10.1097/coc.0000000000000260↗
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Farshid Dayyani · 3 shared papers, 2022–2026 · strength 0.66
- Paper Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer. DOI 10.1016/j.jvir.2026.108954↗
- Paper Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. DOI 10.6004/jnccn.2023.7333↗
- Paper BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. DOI 10.3390/cancers14102453↗
- Jennifer Brooke Valerin · 2 shared papers, 2022–2024 · strength 0.37
- Naomie Devico Marciano · 2 shared papers, 2022–2024 · strength 0.37
- May Thet Cho · 2 shared papers, 2022–2024 · strength 0.37
- Nadine Abi‐Jaoudeh · 1 shared paper, 2026 · strength 0.29
- Jennifer Brooke Goldstein · 1 shared paper, 2026 · strength 0.29
- David K. Imagawa · 1 shared paper, 2026 · strength 0.29
- Ricardo Azevedo · 1 shared paper, 2026 · strength 0.29
- Christopher Ryan Grant · 1 shared paper, 2023 · strength 0.26
- Claudia Rosso · 1 shared paper, 2024 · strength 0.20
- Lucas Wong · 1 shared paper, 2018 · strength 0.08
- Evan M. Hersh · 1 shared paper, 2018 · strength 0.08
- Mark M. Zalupski · 1 shared paper, 2018 · strength 0.08
- Wen Wee Ma · 1 shared paper, 2018 · strength 0.08
- Steven J. Cohen · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.